Questions? Feedback? powered by Olark live chat software
All Site

Luciferase Reporter Cancer Cell Lines

CAR-T cell-based therapeutics have emerged as a promising immunotherapy for treating specific leukemias, lymphomas, and myelomas. In this exciting approach to treating refractory cancers, T cells are isolated from a patient’s blood via apheresis.

- CAR-T cells are a new type of "living" therapeutic
- Harnesses the patient’s immune system to recognize specific tumor-associated antigens
- Redirects the engineered T cells to more specifically target tumor cells.

Click here to find out more:

03.08.2023 | Posted in Blogs;